Business Description
Cinclus Pharma Holding AB
ISIN : SE0020388577
Description
Cinclus Pharma Holding AB is a clinical stage pharmaceutical company developing a drug for the treatment of erosive gastroesophageal reflux diseases, and a dual therapy treatment with an antibiotic targeting Helicobacter pylori which is a bacteria that occurs in the gastric and duodenal mucosa. The Company's main target population is patients suffering from severe eGERD, where there is a lack of satisfactory treatment options.
Financial Strength
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 1464.24 | |||||
| Equity-to-Asset | 0.92 | |||||
| Piotroski F-Score | N/A/9 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History |
|---|
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 31.38 | |||||
| 9-Day RSI | 27.24 | |||||
| 14-Day RSI | 25.87 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 14.8 | |||||
| Quick Ratio | 14.8 | |||||
| Cash Ratio | 14.52 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Shareholder Yield % | -84.47 |
Profitability Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| FCF Margin % | -2733.39 | |||||
| ROE % | -60.06 | |||||
| ROA % | -42.08 | |||||
| ROIC % | -175.2 | |||||
| ROC (Joel Greenblatt) % | -22162.32 | |||||
| ROCE % | -56.58 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 143.12 | |||||
| PB Ratio | 1.51 | |||||
| Price-to-Tangible-Book | 1.52 | |||||
| EV-to-EBIT | -1.8 | |||||
| EV-to-EBITDA | -1.82 | |||||
| EV-to-Revenue | 46.19 | |||||
| EV-to-FCF | -1.72 | |||||
| Price-to-Net-Current-Asset-Value | 1.52 | |||||
| Price-to-Net-Cash | 1.55 | |||||
| Earnings Yield (Greenblatt) % | -55.41 | |||||
| FCF Yield % | -17.72 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Cinclus Pharma Holding AB Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil kr) | 5.959 | ||
| EPS (TTM) (kr) | -4.074 | ||
| Beta | 0 | ||
| Volatility % | 0 | ||
| 14-Day RSI | 25.87 | ||
| 14-Day ATR (kr) | 1.065073 | ||
| 20-Day SMA (kr) | 21.74245 | ||
| 12-1 Month Momentum % | 0 | ||
| 52-Week Range (kr) | 19.116 - 40 | ||
| Shares Outstanding (Mil) | 46.54 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 9999 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Cinclus Pharma Holding AB Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Cinclus Pharma Holding AB Stock Events
| Event | Date | Price(kr) | ||
|---|---|---|---|---|
| No Event Data | ||||
Cinclus Pharma Holding AB Frequently Asked Questions
What is Cinclus Pharma Holding AB(OSTO:CINPHA)'s stock price today?
The current price of OSTO:CINPHA is kr19.75. The 52 week high of OSTO:CINPHA is kr40.00 and 52 week low is kr19.12.
When is next earnings date of Cinclus Pharma Holding AB(OSTO:CINPHA)?
The next earnings date of Cinclus Pharma Holding AB(OSTO:CINPHA) is 2025-02-20.
Does Cinclus Pharma Holding AB(OSTO:CINPHA) pay dividends? If so, how much?
Cinclus Pharma Holding AB(OSTO:CINPHA) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers